Recent sequencing studies have identified EphA3 mutations in lung cancer and other cancers, and functional characterization has revealed that many are loss-of-function mutations that inhibit ephrin binding, kinase activity and/or cell surface localization, suggesting a tumor suppressor role for wild-type EphA3 [14,15,29]. This evidence concerns the gene EPHA3 and lung cancer.